Global Hospital-Acquired Pneumonia Prevention Market Growth 2025-2031

The global Hospital-Acquired Pneumonia Prevention market size is predicted to grow from US$ 185 million in 2025 to US$ 274 million in 2031; it is expected to grow at a CAGR of 6.8% from 2025 to 2031.

Dental plaque is a biofilm formed by bacteria and their excreta, mainly distributed between the gums, and these bacteria cannot be removed using gauze or sponges. Bacteria in the mouth will quickly form a bacterial biofilm and cover the surface of the teeth within two hours after each cleaning. This biofilm protects common pathogens in the ICU, such as Staphylococcus aureus and Klebsiella pneumoniae. This biofilm must be destroyed before using antibacterial agents. If plaque and bacteria cannot be removed, they will move down to the balloon of the endotracheal tube. Since the balloon sealing cannot reach 100%, aspiration pneumonia will occur. Oral care is one of the effective means to prevent hospital-acquired pneumonia.

In hospitals, oral care is a vital measure to prevent aspiration pneumonia (i.e., hospital-acquired pneumonia), especially for bedridden patients, the elderly, patients with weakened immunity, and critically ill patients. This is because if the bacteria in the mouth are not effectively removed, they may enter the lungs through aspiration (i.e., swallowing saliva, food, or oral secretions), thus causing pneumonia. With the advancement of medical technology and the improvement of patients' awareness of hospital infection prevention and control, the prevention measures of hospital-acquired pneumonia have gradually gained attention. Globally, the prevention market of hospital-acquired pneumonia has gradually developed with the changes in public health needs and medical environment. The prevention market of hospital-acquired pneumonia included in this report is mainly oral care products.

Oral care products usually include oral care kits, moisturizing gels, mouthwashes, etc., among which oral care kits accounts for the largest proportion.

From the application point of view, patients in intensive care units (ICUs) are usually in an immunosuppressive state, and the risk of pneumonia infection is higher than that of patients in ordinary wards. Oral care has become an important part of reducing infection and preventing pneumonia. In order to reduce the incidence of hospital-acquired pneumonia in ICU patients, the use of oral care kits has become one of the standard preventive measures. The proportion in 2023 is approximately 60%.

The global key players of HAP prevention include Stryker, Medline, Ecolab, Avanos, Dentsply Sirona, Intersurgical and Dentaid, etc. In 2023, in term of revenue of HAP prevention, the top 3 companies hold a share nearly 43%.

The problem of antibiotic resistance is becoming more and more serious, and traditional antibiotic treatment is no longer the only way to deal with hospital-acquired pneumonia. Preventive measures, such as the use of oral care kits, can effectively reduce bacterial loads and reduce the need for antibiotics, thereby alleviating the problem of drug resistance.

LP Information, Inc. (LPI) ' newest research report, the “Hospital-Acquired Pneumonia Prevention Industry Forecast” looks at past sales and reviews total world Hospital-Acquired Pneumonia Prevention sales in 2024, providing a comprehensive analysis by region and market sector of projected Hospital-Acquired Pneumonia Prevention sales for 2025 through 2031. With Hospital-Acquired Pneumonia Prevention sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hospital-Acquired Pneumonia Prevention industry.

This Insight Report provides a comprehensive analysis of the global Hospital-Acquired Pneumonia Prevention landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hospital-Acquired Pneumonia Prevention portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hospital-Acquired Pneumonia Prevention market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hospital-Acquired Pneumonia Prevention and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hospital-Acquired Pneumonia Prevention.

This report presents a comprehensive overview, market shares, and growth opportunities of Hospital-Acquired Pneumonia Prevention market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Oral Care Kit
Moisturizer Gel
Mouth Wash
Others

Segmentation by Application:
General Ward
Intensive Care Unit

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Stryker
Medline
Ecolab
Avanos
Dentsply Sirona
Intersurgical
Dentaid
Xttrium
Germiphene

Key Questions Addressed in this Report

What is the 10-year outlook for the global Hospital-Acquired Pneumonia Prevention market?

What factors are driving Hospital-Acquired Pneumonia Prevention market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Hospital-Acquired Pneumonia Prevention market opportunities vary by end market size?

How does Hospital-Acquired Pneumonia Prevention break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.